Avidity Biosciences (RNA) Accumulated Expenses (2019 - 2025)
Historic Accumulated Expenses for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $137.2 million.
- Avidity Biosciences' Accumulated Expenses rose 65194.89% to $137.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.2 million, marking a year-over-year increase of 65194.89%. This contributed to the annual value of $64.7 million for FY2024, which is 35152.42% up from last year.
- According to the latest figures from Q3 2025, Avidity Biosciences' Accumulated Expenses is $137.2 million, which was up 65194.89% from $95.2 million recorded in Q2 2025.
- In the past 5 years, Avidity Biosciences' Accumulated Expenses ranged from a high of $137.2 million in Q3 2025 and a low of $2.7 million during Q1 2021
- Over the past 5 years, Avidity Biosciences' median Accumulated Expenses value was $8.9 million (recorded in 2021), while the average stood at $22.9 million.
- Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 2516.78% in 2022, then surged by 65194.89% in 2025.
- Over the past 5 years, Avidity Biosciences' Accumulated Expenses (Quarter) stood at $8.9 million in 2021, then increased by 25.17% to $11.2 million in 2022, then increased by 28.11% to $14.3 million in 2023, then soared by 351.52% to $64.7 million in 2024, then soared by 111.91% to $137.2 million in 2025.
- Its Accumulated Expenses was $137.2 million in Q3 2025, compared to $95.2 million in Q2 2025 and $12.8 million in Q1 2025.